Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.62 - $0.85 $265,085 - $363,423
-427,557 Reduced 81.12%
99,532 $83,000
Q4 2023

Feb 14, 2024

SELL
$0.67 - $1.35 $31,861 - $64,197
-47,554 Reduced 8.28%
527,089 $363,000
Q3 2023

Nov 14, 2023

BUY
$1.02 - $1.23 $19,707 - $23,764
19,321 Added 3.48%
574,643 $609,000
Q2 2023

Aug 14, 2023

BUY
$1.04 - $1.4 $49,543 - $66,693
47,638 Added 9.38%
555,322 $621,000
Q1 2023

May 15, 2023

BUY
$1.15 - $1.89 $373,962 - $614,599
325,185 Added 178.18%
507,684 $705,000
Q4 2022

Feb 14, 2023

SELL
$0.96 - $1.6 $638,884 - $1.06 Million
-665,505 Reduced 78.48%
182,499 $206,000
Q3 2022

Nov 14, 2022

BUY
$1.33 - $2.6 $765,932 - $1.5 Million
575,889 Added 211.63%
848,004 $1.39 Million
Q2 2022

Aug 15, 2022

SELL
$0.67 - $1.4 $22,926 - $47,906
-34,219 Reduced 11.17%
272,115 $357,000
Q1 2022

May 16, 2022

BUY
$1.23 - $3.31 $87,882 - $236,496
71,449 Added 30.42%
306,334 $377,000
Q4 2021

Feb 14, 2022

BUY
$2.89 - $4.43 $378,685 - $580,476
131,033 Added 126.17%
234,885 $765,000
Q3 2021

Nov 15, 2021

SELL
$3.36 - $4.62 $55,245 - $75,962
-16,442 Reduced 13.67%
103,852 $432,000
Q2 2021

Aug 16, 2021

SELL
$2.82 - $5.01 $239,590 - $425,654
-84,961 Reduced 41.39%
120,294 $502,000
Q1 2021

May 17, 2021

BUY
$2.92 - $5.07 $262,446 - $455,686
89,879 Added 77.9%
205,255 $929,000
Q4 2020

Feb 16, 2021

BUY
$1.64 - $3.42 $161,226 - $336,216
98,309 Added 576.02%
115,376 $350,000
Q3 2020

Nov 16, 2020

BUY
$2.18 - $2.84 $37,206 - $48,470
17,067 New
17,067 $42,000
Q2 2020

Aug 14, 2020

SELL
$1.83 - $4.06 $3.1 Million - $6.88 Million
-1,695,330 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.5 - $4.52 $2.51 Million - $7.56 Million
1,673,163 Added 7547.99%
1,695,330 $4.09 Million
Q4 2018

Feb 14, 2019

BUY
$2.66 - $15.93 $58,964 - $353,120
22,167 New
22,167 $58,000

Others Institutions Holding SELB

About SELECTA BIOSCIENCES INC


  • Ticker SELB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 152,712,992
  • Market Cap $128M
  • Description
  • Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...
More about SELB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.